Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada

PharmacoEconomics

Volumn 26, Issue 6, 2008, Pages 477-495

  Marshall, Deborah A ^a,b,c   Douglas, Patrick R ^a   Drummond, Michael F ^a,d   Torrance, George W ^a,b   MacLeod, Stuart ^a,e   Manti, Orlando ^f   Cheruvu, Lokanadha ^f   Corvari, Ron ^f  

^a Health Economics and Outcomes Research   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^d UNIVERSITY OF YORK   (United Kingdom)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Patented Med Prices Review Board   (Canada)

Author keywords

Budget impact analysis; Guideline utilisation

Indexed keywords

BUDGET; CANADA; DRUG COST; DRUG UTILIZATION; ECONOMIC ASPECT; HEALTH CARE COST; MODEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; STANDARDIZATION; VALIDATION PROCESS;

BUDGETS; CANADA; COSTS AND COST ANALYSIS; DRUG COSTS; GUIDELINES AS TOPIC; INSURANCE, PHARMACEUTICAL SERVICES;

EID: 44049087446     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826060-00003     Document Type: Review

References (17)

1. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for economic evaluation of health technologies: Canada. 3rd ed. Ottawa: CADTH, 2006
2. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Common drug review submission guidelines for manufacturers. Ottawa: CCOHTA, 2005 Jul 25
3. Alberta Health and Wellness. Budget impact assessment for the Alberta Health and Wellness drug benefit list, version 6. July 2006 [online]. Available from URL: http://www.ab.bluecross.ca/dbl/pdfs/bia2006.pdf [Accessed 2006 Oct 13]
4. Manitoba Health. Budget impact assessment for the Manitoba Health Manitoba drug benefits and interchangeability formulary. 2003 Jul 30 [online]. Available from URL: http://www.gov.mb.ca/health/documents/bia.doc [Accessed 2006 Oct 13]
5. Ontario Ministry of Health and Long-Term Care. Ontario Drug Benefits Program: Ontario guidelines for drug submission and evaluation [online]. Available from URL: http://www.health.gov.on.ca/english/providers/pub/drugs/ dsguide/dsguide_mn.html [Accessed 2006 Oct 13]
6. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada. Ottawa: CCOHTA, 1994
7. Patented Medicine Prices Review Board. Budget impact analysis guidelines: needs assessment. Ottawa: Patented Medicine Prices Review Board, 2005
8. International Society for Pharmacoeconomics and Outcomes Research. Pharmacoeconomic guidelines around the world [online]. Available from URL: http://www.ispor.org/PEguidelines/index.asp [Accessed 2007 Jun 17]
9. Patented Medicine Prices Review Board. Budget impact analysis guidelines: guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Ottawa: Patented Medicine Prices Review Board, 2007 [online]. Available from URL: http://www.pmprbcepmb.gc.ca/CMFiles/BIA- may0738LVV-5282007-5906.pdf [Accessed 2007 Nov 27]
10. Patented Medicine Prices Review Board. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada: budget impact analysis model template. Ottawa: Patented Medicine Prices Review Board, 2007 [online]. Available from URL: http://www.pmprbcepmb.gc.ca/ CMFiles/PMPRB_-_Final_BIA_Template_138LWA-5282007-6476.0_-
11. Greenberg JD, Bingham III CO, Abramson SB, et al. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. Arthritis Rheum 2006 Aug 15; 55 (4): 543-50
12. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003; 6 (1): 9-17
13. Dickson M, Hurst J, Jacobzone S. Survey of pharmacoeconomic assessment activity in eleven countries [OECD Health Working Papers 4]. Paris: OECD Directorate for Employment, Labour and Social Affairs, 2003 May 16
14. Commonwealth of Australia Department of Health and Ageing (DoHaA), editor. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Commonwealth of Australia DoHaA. Canberra (ACT): Commonwealth of Australia, DoHaA, 2002
15. National Institute for Health and Clinical Excellence. Specification for manufacturer/sponsor submission of evidence [online]. Available from URL: http://www.nice.org.uk/page.aspx?.o=356870 [Accessed 2007 Jun 17]
16. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on Good Research Practices - Budget Impact Analysis. Value Health 2007; 10: 336-47
17. Orlewska E, Mierzejewski P. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health 2004; 7 (1): 1-10